Literature DB >> 10409394

Metabolism of arsenic in primary cultures of human and rat hepatocytes.

M Styblo1, L M Del Razo, E L LeCluyse, G A Hamilton, C Wang, W R Cullen, D J Thomas.   

Abstract

The liver is considered a major site for methylation of inorganic arsenic (iAs). However, there is little data on the capacity of human liver to methylate iAs. This work examined the metabolism of arsenite (iAs(III)), arsenate (iAs(V)), methylarsine oxide (MAs(III)O), methylarsonic acid (MAs(V)), dimethylarsinous acid (DMAs(III)), and dimethylarsinic acid (DMAs(V)) in primary cultures of normal human hepatocytes. Primary rat hepatocytes were used as methylating controls. iAs(III) and MAs(III)O were metabolized more extensively than iAs(V) and MAs(V) by either cell type. Neither human nor rat hepatocytes metabolized DMAs(III) or DMAs(V). Methylation of iAs(III) by human hepatocytes yielded methylarsenic (MAs) and dimethylarsenic (DMAs) species; MAs(III)O was converted to DMAs. The total methylation yield (MAs and DMAs) increased over the range of 0.1 to 4 microM iAs(III). However, DMAs production was inhibited by iAs(III) in a concentration-dependent manner, and the DMAs/MAs ratio decreased. iAs(III) (10 and 20 microM) inhibited both methylation reactions. Inhibition of DMAs synthesis resulted in accumulation of iAs and MAs in human hepatocytes, suggesting that dimethylation is required for iAs clearance from cells. Methylation capacities of human hepatocytes obtained from four donors ranged from 3.1 to 35.7 pmol of iAs(III) per 10(6) cells per hour and were substantially lower than the methylation capacity of rat hepatocytes (387 pmol of iAs(III) per 10(6) cells per hour). The maximal methylation rates for either rat or human hepatocytes were attained between 0.4 and 4 microM iAs(III). In summary, (i) human hepatocytes methylate iAs, (ii) the capacities for iAs methylation vary among individuals and are saturable, and (iii) moderate concentrations of iAs inhibit DMAs synthesis, resulting in an accumulation of iAs and MAs in cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10409394     DOI: 10.1021/tx990050l

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  29 in total

1.  Arsenicals in maternal and fetal mouse tissues after gestational exposure to arsenite.

Authors:  Vicenta Devesa; Blakely M Adair; Jie Liu; Michael P Waalkes; Bhalchandra A Diwan; Miroslav Styblo; David J Thomas
Journal:  Toxicology       Date:  2006-05-03       Impact factor: 4.221

2.  Expression of AS3MT alters transcriptional profiles in human urothelial cells exposed to arsenite.

Authors:  Sd Hester; Z Drobná; Dmk Andrews; J Liu; Mp Waalkes; Dj Thomas; M Styblo
Journal:  Hum Exp Toxicol       Date:  2009-01       Impact factor: 2.903

3.  Tissue dosimetry, metabolism and excretion of pentavalent and trivalent monomethylated arsenic in mice after oral administration.

Authors:  Michael F Hughes; Vicenta Devesa; Blakely M Adair; Miroslav Styblo; Elaina M Kenyon; David J Thomas
Journal:  Toxicol Appl Pharmacol       Date:  2005-10-15       Impact factor: 4.219

4.  A pathway-based analysis of urinary arsenic metabolites and skin lesions.

Authors:  Molly L Kile; Elaine Hoffman; Ema G Rodrigues; Carrie V Breton; Quazi Quamruzzaman; Mahmuder Rahman; Golam Mahiuddin; Yu-Mei Hsueh; David C Christiani
Journal:  Am J Epidemiol       Date:  2011-03-04       Impact factor: 4.897

5.  Histopathological alterations in Senegal sole, Solea Senegalensis, from a polluted Huelva estuary (SW, Spain).

Authors:  M Oliva; J J Vicente-Martorell; M D Galindo-Riaño; J A Perales
Journal:  Fish Physiol Biochem       Date:  2012-09-26       Impact factor: 2.794

6.  Metabolism and toxicity of arsenic in human urothelial cells expressing rat arsenic (+3 oxidation state)-methyltransferase.

Authors:  Zuzana Drobná; Stephen B Waters; Vicenta Devesa; Anne W Harmon; David J Thomas; Miroslav Stýblo
Journal:  Toxicol Appl Pharmacol       Date:  2005-09-01       Impact factor: 4.219

7.  Pharmacokinetic modeling of arsenite uptake and metabolism in hepatocytes--mechanistic insights and implications for further experiments.

Authors:  Michael R Easterling; Miroslav Styblo; Marina V Evans; Elaina M Kenyon
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-06       Impact factor: 2.745

8.  Development of a human physiologically based pharmacokinetic (PBPK) model for inorganic arsenic and its mono- and di-methylated metabolites.

Authors:  Hisham A El-Masri; Elaina M Kenyon
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-10-18       Impact factor: 2.745

9.  Folate and cobalamin modify associations between S-adenosylmethionine and methylated arsenic metabolites in arsenic-exposed Bangladeshi adults.

Authors:  Caitlin G Howe; Megan M Niedzwiecki; Megan N Hall; Xinhua Liu; Vesna Ilievski; Vesna Slavkovich; Shafiul Alam; Abu B Siddique; Joseph H Graziano; Mary V Gamble
Journal:  J Nutr       Date:  2014-03-05       Impact factor: 4.798

10.  Association Between Variants in Arsenic (+3 Oxidation State) Methyltranserase (AS3MT) and Urinary Metabolites of Inorganic Arsenic: Role of Exposure Level.

Authors:  Xiaofan Xu; Zuzana Drobná; V Saroja Voruganti; Keri Barron; Carmen González-Horta; Blanca Sánchez-Ramírez; Lourdes Ballinas-Casarrubias; Roberto Hernández Cerón; Damián Viniegra Morales; Francisco A Baeza Terrazas; María C Ishida; Daniela S Gutiérrez-Torres; R Jesse Saunders; Jamie Crandell; Rebecca C Fry; Dana Loomis; Gonzalo G García-Vargas; Luz M Del Razo; Miroslav Stýblo; Michelle A Mendez
Journal:  Toxicol Sci       Date:  2016-06-30       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.